COMPANY

Atara Biotherapeutics

Keywords: oncology immunology cancer cell therapy EBV-induced Lymphomas EBV-associated Malignancies Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Lupus Nephritis Systemic Lupus Erythematosus Nasopharyngeal Carcinoma Nasopharyngeal Neoplasms Epstein-Barr Virus Infections Epstein-Barr Viraemia Epstein-Barr Virus-associated Nasopharyngeal Carcinoma Primary Progressive Multiple Sclerosis Secondary Progressive Multiple Sclerosis Epstein-Barr Virus (EBV) Infections Lymphoproliferative Disorders EBV+ Associated Lymphoma EBV+ Associated Post-transplant Lymphoproliferative Disease Epstein-Barr Viremia AIDS-related Lymphoma Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID) Leiomyosarcoma Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID) Solid Organ Transplant Complications Stem Cell Transplant Complications CMV Viremia CMV Disease ATA3219 ATA188 tabelecleucel Epstein-Barr virus-specific cytotoxic T lymphocytes EBV-specific T cells Cytomegalovirus-specific Cytotoxic T Lymphocytes

Profile checked Oct 10, 2026

8Trials (company is sponsor)

Timeline

Apr 16, 2025 Trial start Phase 1: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus source ↗
Sep 6, 2024 Trial start Phase 1: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma source ↗
Feb 19, 2019 Trial start Phase 1/Phase 2: Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) source ↗
Oct 19, 2017 Trial start 1: Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis source ↗
2011-12 Trial start Phase 2: Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorder source ↗
1995-03 Trial start Phase 1/Phase 2: Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies source ↗

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT06256484	A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma	Phase 1	Terminated	Sep 6, 2024	Mar 3, 2025 (actual)
NCT06429800	A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus	Phase 1	Withdrawn	Apr 16, 2025	Apr 16, 2025 (actual)
NCT03769467	Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)	Phase 1/Phase 2	Terminated	Feb 19, 2019	Aug 19, 2021 (actual)
NCT03283826	Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis	1	Terminated	Oct 19, 2017	Nov 9, 2023 (actual)
NCT02822495	Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies	Not listed	No longer available	Not listed	Not listed
NCT00002663	Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies	Phase 1/Phase 2	Completed	1995-03	2019-07 (actual)
NCT01498484	Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies	Phase 2	Completed	2011-12	2019-07 (actual)
NCT03010332	Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease	Not listed	No longer available	Not listed	Not listed